TH-302 in Combination With Bevacizumab for Glioblastoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
The University of Texas Health Science Center at San Antonio
Study ID
NCT02342379
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.

Key Dates

First listed
Jan 19, 2015
Start date
May 31, 2015
Status verified
Apr 2020
Primary completion
Jan 4, 2019
Completion
Dec 4, 2019

Study Design

Enrollment
35 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab and TH-302
    Patients will be treated with combination of bevacizumab and TH-302.

Primary Outcome Measure

Number of Patients With Adverse Events [ Time Frame: 4 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
Dana-Farber Cancer InstituteBostonMassachusetts02215-
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research CenterSan AntonioTexas78229-

Find similar trials in Boston, MA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Dana-Farber Cancer Institute· Boston, MAUniversity of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center· San Antonio, TX

Related Studies